Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Codexis Inc

CDXS
Current price
2.47 USD +0.07 USD (+2.92%)
Last closed 2.36 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 141 755 312 USD
Yield for 12 month -58.35 %
Week
Month
Year
CDXS
21.11.2021 - 28.11.2021

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California. Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063

Analytics

WallStreet Target Price

5.83 USD

P/E ratio

Dividend Yield

2.84 %

Current Year

+138 590 000 USD

Last Year

+104 754 000 USD

Current Quarter

+9 277 000 USD

Last Quarter

+21 323 000 USD

Current Year

+100 557 000 USD

Last Year

+82 545 000 USD

Current Quarter

+7 028 000 USD

Last Quarter

+18 145 000 USD

Key Figures CDXS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -59 404 000 USD
Operating Margin TTM -204.12 %
PE Ratio
Return On Assets TTM -20.9 %
PEG Ratio -1.16
Return On Equity TTM -66.48 %
Wall Street Target Price 5.83 USD
Revenue TTM 73 957 000 USD
Book Value 1.32 USD
Revenue Per Share TTM 1.1 USD
Dividend Share
Quarterly Revenue Growth YOY -73.1 %
Dividend Yield 2.84 %
Gross Profit TTM 20 458 000 USD
Earnings Share -1.21 USD
Diluted Eps TTM -1.21 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -110.41 %

Dividend Analytics CDXS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CDXS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.84 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CDXS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 138.8889
Enterprise Value Revenue 2.281
Price Sales TTM 2.7321
Enterprise Value EBITDA -13.3874
Price Book MRQ 2.3781

Financials CDXS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CDXS

For 52 weeks

1.45 USD 6.98 USD
50 Day MA 1.82 USD
Shares Short Prior Month 2 518 282
200 Day MA 2.94 USD
Short Ratio 4.1
Shares Short 2 765 360
Short Percent 4.05 %